Download full report with analyst certification and important disclosures
Oct 11 2023, 07:00 IST/BST
hVIVO
Specialist in human challenge trials
- Sectors : Pharma and healthcare
- Companies : hVIVO
DAVY VIEW
We are re-initiating coverage of hVIVO (HVO) with an ‘Outperform’ rating and a price target of 29p per share. Our investment thesis hinges on the robust industry growth outlook. HVO is extremely well positioned to capitalise on this.
